MSD, also known as Merck in North America, has taken a significant step to enhance its therapeutic portfolio by investing $1.3 billion in the acquisition of CN201 from Curon Biopharmaceutical. The investigational bispecific antibody is poised to change the landscape of treatments for B-cell
The journey from a new chemical entity (NCE) to a marketable drug product is a complex, multifaceted process that demands an intricate blend of scientific expertise and practical knowledge. The transformation involves a deep understanding of organic chemistry, analytical development, pharmaceutical
Clinical trials are the bedrock upon which medical advancements are discovered and validated. However, the traditional processes involved in clinical trials are fraught with inefficiencies, high costs, and prolonged durations that hinder timely medical innovations. Ushur, a leader in AI-powered
The biopharma sector is at an inflection point as the United States grapples with concerns about China's influence and potential risks posed by collaborations with Chinese military medical institutions. A legislative measure known as the BIOSECURE Act aims to address these apprehensions,
Tanvex BioPharma USA, Inc., a frontrunner in biologics development, has made significant strides by securing FDA approval for NYPOZI (filgrastim-txid) and advancing its Biologics License Application (BLA) for TX-05. These milestones underscore the company’s unwavering commitment to delivering h
Accenture, a global professional services company renowned for its expertise in strategy, consulting, and technology, has made a strategic investment in Earli Inc., a biotechnology firm dedicated to revolutionary early cancer detection. This strategic move is managed through Accenture Ventures and
Novo Nordisk has announced a significant expansion of its manufacturing capabilities at its Køge site in Denmark, aiming to address the soaring global demand for its diabetes and obesity treatments. As one of the leading pharmaceutical companies worldwide, this move underlines Novo Nordisk's
The latest findings from Kiromic BioPharma’s phase 1/2 clinical trial spotlight the promising potential of its investigational therapy, Deltacel (KB-GDT-01), an allogeneic gamma delta T-cell (GDT) therapy. This novel therapy is being evaluated for patients with non-small cell lung cancer (NSCLC) w
Navigating the stock market requires an astute understanding of both the company's financial health and the external market conditions. Sutro Biopharma Inc. (NASDAQ: STRO), which operates in the volatile biopharma sector, exemplifies the potential and pitfalls of high-risk, high-reward
Single-use systems (SUS) have revolutionized biopharmaceutical manufacturing, with single-use bioreactors (SUBs) leading the charge in recent decades. However, while the adoption of SUBs has plateaued, other forms of single-use technology (SUT) are gaining momentum. The landscape is evolving
